Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...

September 19, 2023

Feature

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Avenue Therapeutics (NASDAQ:ATXI) has taken a quantum leap into the CNS space during landscape over the past 12 months by adding two early-stage clinical assets to its pipeline to complement its late-stage intravenous...

September 12, 2023

Feature

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.

September 5, 2023

Feature

Convergent readies IND for next-gen targeted radiotherapy

Closely-held Convergent Therapeutics is rapidly advancing a next generation alpha-emitting prostate-specific membrane antigen (PSMA)-targeted radioantibody for an IND filing in October.

August 29, 2023

Feature

Halia targeting chronic inflammation to keep people healthier, living longer

Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and...

August 22, 2023

Feature

Immuneering developing medicines for cancer patients with RAS mutations

Immuneering (NASDAQ:IMRX) is integrating translational medicine with bioinformatics to discover and develop novel product candidates for a broad population of cancer patients with RAS mutations, an approach the company...

August 15, 2023

Feature

Apollomics focused on difficult-to-treat cancers using precision medicine

Apollomics (NASDAQ:APLM) is developing a pipeline of nine novel drug candidates across multiple programs, six of which are now in the clinical stage of development and two in late-stage studies.

August 8, 2023

Feature

ImmunoBrain thinking outside the brain to defeat neurodegenerative diseases

Closely-held ImmunoBrain Checkpoint, with its R&D team in Israel, is pursuing a unique approach that targets the peripheral immune system, rather than directly targeting the brain in patients suffering from Alzheimer’s...

August 1, 2023

Feature

Anixa vaccines targeting unique mechanism in breast, ovarian cancer

Anixa Biosciences (NASDAQ:ANIX) is targeting a unique technology in two early-stage, first-in-class prophylactic cancer vaccines with the potential to prevent cancer cells from forming into breast and ovarian tumors.

July 25, 2023

Feature

Transforming lives with 3D-printed prosthetic hand

As CEO of the Victoria Hand Project, a charity spun out of the University of Victoria in British Columbia, Michael Peirone is a jack of all trades: engineering, operations, IP, business strategy, fundraising and...

July 18, 2023

Feature

Monogram next gen robot seeks to disrupt orthopedic market

Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...

July 11, 2023

Feature

Cantex’s azeliragon in cancer, prevention of acute kidney injury trials

Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...

July 4, 2023

Feature

Chinook on a mission to change the course of kidney care

Chinook Therapeutics (NASDAQ:KDNY), which is developing three drug candidates to change the course of kidney care as well as a precision medicine pipeline of R&D programs, received a shot in the arm this month when...

June 27, 2023

This Week's Feature

Centessa focused on asset-centric, patient-centric drug development

Centessa Pharmaceuticals (NASDAQ:CNTA) is developing a portfolio of innovative drug candidates with small, focused R&D teams, a model it calls “asset-centric.”

June 20, 2023

Feature

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.

June 13, 2023

Feature

Avivo developing universal donor blood type to expand transplants, safer transfusions

John Coleman, Ph.D., envisions a future where blood types cease to be a primary constraint in life-saving organ transplants and blood transfusions. “Recognizing the urgent need for solutions to these challenges, we have...

June 6, 2023

Feature

Virax Biolabs readies clinical performance study of ViraxImmune Platform

Virax Biolabs (NASDAQ:VRAX) expects to begin in the third quarter a clinical performance study of its proprietary T-Cell testing platform, ViraxImmune, as a stepping stone for regulatory compliance in the U.S. and...

May 30, 2023

Feature

HDT Bio focused on global impact of mRNA vaccine platform

HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.

May 23, 2023

Feature

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for the treatment of mild Alzheimer’s disease (AD).

May 16, 2023

Feature

Peptilogics lead peptide platform targeting serious joint replacement infections

Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...

May 9, 2023

Feature

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

UK based biotechnology company SynaptixBio is developing the world’s first life-saving medicine for TUBB4A leukodystrophy, a rare genetic neurodegenerative disease that affects approximately 1,600 newborn babies and...

May 2, 2023

Feature

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...

April 25, 2023

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Convergent readies IND for next-gen targeted radiotherapy

Halia targeting chronic inflammation to keep people healthier, living longer

Immuneering developing medicines for cancer patients with RAS mutations

Apollomics focused on difficult-to-treat cancers using precision medicine

ImmunoBrain thinking outside the brain to defeat neurodegenerative diseases

Anixa vaccines targeting unique mechanism in breast, ovarian cancer

Transforming lives with 3D-printed prosthetic hand

Monogram next gen robot seeks to disrupt orthopedic market

Cantex’s azeliragon in cancer, prevention of acute kidney injury trials

Chinook on a mission to change the course of kidney care

Centessa focused on asset-centric, patient-centric drug development

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

Avivo developing universal donor blood type to expand transplants, safer transfusions

Virax Biolabs readies clinical performance study of ViraxImmune Platform

HDT Bio focused on global impact of mRNA vaccine platform

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Peptilogics lead peptide platform targeting serious joint replacement infections

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

EyePoint focused on long-lasting treatments for wet AMD and DR

General

More